BENDAZAC LYSINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H14N2O3.C6H14N2O2
Molecular Weight	428.4815
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NCCCC[C@H](N)C(O)=O.OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3

InChI

InChIKey=OCOCFNMFLNFNIA-ZSCHJXSPSA-N

InChI=1S/C16H14N2O3.C6H14N2O2/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12;7-4-2-1-3-5(8)6(9)10/h1-9H,10-11H2,(H,19,20);5H,1-4,7-8H2,(H,9,10)/t;5-/m.0/s1

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2190795
Curator's Comment: description was created based on several sources, including: http://database.japic.or.jp/pdf/newPINS/00056628.pdf http://www.kegg.jp/medicus-bin/japic_med?japic_code=00056628 http://www.ncbi.nlm.nih.gov/pubmed/5317253

Bendazac, (1-benzyl-1H-indazol-3-yl-oxy)-acetic acid, is structurally related to indomethacin. Its lysine salt has been reported to be absorbed better than the parent compound. It is applied topically as bendazac lysine 0.5% (wt/vol) aqueous solution for delaying the progression of cataract. Topical application of bendazac is associated with transient burning sensation. It reduces the secretion of the skin ulcer surface, promotes skin formation and accelerates tissue repair.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
reactive oxygen species 8 Target ID: reactive oxygen species Sources: http://www.ncbi.nlm.nih.gov/pubmed/8736488	Modulator 828
Xanthine dehydrogenase/oxidase 41 Target ID: CHEMBL1075246 Sources: http://www.ncbi.nlm.nih.gov/pubmed/21781693	Inhibitor 8297		0.33 mM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Burn ulcer and radiation ulcers 4 Sources: http://database.japic.or.jp/pdf/newPINS/00056628.pdf	Primary	Approved 8429	Zildasac Ointment Approved Use Indications: Pressure sores, burns ulcers, radiation ulcers; Contact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Contact dermatitis 20 Sources: http://database.japic.or.jp/pdf/newPINS/00056628.pdf	Primary	Approved 8429	Zildasac Ointment Approved Use Indications: Pressure sores, burns ulcers, radiation ulcers; Cntact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Eczema 46 Sources: http://database.japic.or.jp/pdf/newPINS/00056628.pdf	Primary	Approved 8429	Zildasac Ointment Approved Use Indications: Pressure sores, burns ulcers, radiation ulcers; Cntact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Psoriasis vulgaris 5 Sources: http://database.japic.or.jp/pdf/newPINS/00056628.pdf	Primary	Approved 8429	Zildasac Ointment Approved Use Indications: Pressure sores, burns ulcers, radiation ulcers; Cntact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Herpes zoster infections 15 Sources: http://database.japic.or.jp/pdf/newPINS/00056628.pdf	Palliative	Approved 8429	Zildasac Ointment Approved Use Indications: Pressure sores, burns ulcers, radiation ulcers; Cntact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Cataract 15 Sources: http://www.120ty.net/bencandy.php?fid=52&id=44224	Primary	Approved 8429	BENDAZAC LYSINE Approved Use Adjuvant in the treatment of cataracts (cataract degenerative presenile and senile, juvenile cataracts, diabetic cataract, opacification of the cortex or the crystalline core of different origin and nature)

PubMed

Title	Date	PubMed
Antidenaturant drugs for cataract and other condensation diseases.	2001 Jan	11133267
Bendazac lysine inhibition of human lens epithelial cell adhesion to polymethylmethacrylate intraocular lenses.	2004 May-Jun	15103205
Topical ocular delivery of NSAIDs.	2008 Jun	18437583
Gene expression profiling in rat liver treated with compounds inducing elevation of bilirubin.	2009 Apr	19734275
Advances in pharmacological strategies for the prevention of cataract development.	2009 May-Jun	19384010
Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents.	2010 Apr 1	20223660

Patents

Sample Use Guides

In Vivo Use Guide

Single Dose Eye drops: 2 drops in each eye or half the contents of a single-dose, three times a day Multi-dose eye drops: 2 drops in each eye, three times a day oral: single dosage benzadac lysine in tables (500 mg) Skin ulcers: An appropriate amount of this product is applied to the affected area several times a day. Incidentally, it performs patch therapy 1-2 times daily as needed. Inflammatory skin disease: An appropriate amount of this product is applied to the affected area several times a day.

Route of Administration: Other

In Vitro Use Guide

The inhibition of labelled cyanate binding to lens proteins increased with increasing concentration of bendazac (max at 40 mM).

Name

Type

Language

BENDAZAC LYSINE

Common Name

English

BENDAZAC LYSINE SALT [MI]

Common Name

English

BENDAZAC LYSINE [MART.]

Common Name

English

BENDAZAC LYSINATE

Common Name

English

BENDAZAC LYSINE SALT

Common Name

English

L-LYSINE-(1-BENZYL-1H-INDAZOL-3-YLOXY)ACETIC ACID

Systematic Name

English

Bendazac lysinate [WHO-DD]

Common Name

English

AF-1934

Code

English

L-LYSINE, 2-((1-(PHENYLMETHYL)-1H-INDAZOL-3-YL)OXY)ACETATE (1:1)

Common Name

English

AF 1934

Code

English

Code System Code Type Description

FDA UNII

CL7T957EGC